pat_auckland said:They are two different exemptions from the same federal requirements and they buy different things.
Agreed, and the enforcement dates were staggered by category — 503A first, 503B a few weeks later — because outsourcing facilities have manufactured inventory and clinic contracts to unwind while a 503A makes to order.
tommy_boulder said:Agreed on the mechanism, with the caveat that the head-to-head used semaglutide 1mg, not 2.4mg.
That reframing is the part I needed.
pat_auckland said:They are two different exemptions from the same federal requirements and they buy different things.
Filing a mild objection. Mild because I might be wrong; an objection because nobody has addressed the case that does not fit. A research-chemical supplier selling lyophilised powder labelled research use only is not compounding and is not claiming to. It is a different legal universe with no pharmacy oversight, no patient relationship and no content guarantee, and conflating the two in these threads helps nobody.
Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.
View ResultsThe figures, for anyone assembling their own picture. Keep the original post as written when you update it, and add the correction underneath. An edited-away mistake is invisible to the next person who makes it.
Moderator note: good thread. Keeping it here rather than moving it, because the question is general enough to be useful. No action needed from anybody.